Grade: F — Major Red Flags
Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles
Data: SEC EDGAR 10-K (Filed 2026-02-23, FY ended December 31, 2025) + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP — Unqualified opinion (1 critical audit matter: Skin Health goodwill impairment)
One-line verdict: Colgate-Palmolive's F grade masks an operationally excellent business behind an engineered balance sheet. The company generates 60.1% gross margins, $4.2B in operating cash flow, and CFFO/NI of 1.97 — yet goodwill+intangibles of $4.7B represent 8,626% of shareholder equity because cumulative share buybacks have reduced equity to just $54M. This is deliberate financial engineering, not distress. The genuine risk lies elsewhere: PwC flagged a $582M goodwill impairment charge on the Skin Health reporting unit in Q4 2025, with "changes in circumstances" triggering an interim review. The M-Score of -3.02 is clean, revenue is growing organically across all segments, and free cash flow of $3.6B funds both $3.3B in annual share repurchases and dividends.
| Metric | Result |
|---|---|
| ❌ Red Flags | **2** (Cash-to-debt, goodwill+intangibles vs equity) |
| ⚠️ Watch Items | **1** (AR growth 10.1% vs revenue 1.4%) |
| Checks Completed | **17/18** (1 N/A: impairment data) |
| Beneish M-Score | **-3.02** (clean) |
| Auditor | PricewaterhouseCoopers LLP — Unqualified opinion, 1 critical audit matter |
A Global Franchise with Near-Zero Equity
Per the filing, Colgate operates in two segments: Oral, Personal and Home Care; and Pet Nutrition (Hill's). "Sales of Oral, Personal and Home Care products accounted for 44%, 17% and 16%, respectively, of our total worldwide Net sales."
| Metric | FY2023 | FY2024 | FY2025 | Trend |
|---|---|---|---|---|
| Net Sales | $19.5B | $20.1B | $20.4B | +4.7% over 3 years |
| Net Income | $2.3B | $2.9B | $2.1B | FY2025 hit by impairment |
| Gross Margin | 58.2% | 60.5% | 60.1% | World-class, stable |
| Net Margin | 11.8% | 14.4% | 10.5% | FY2025 depressed by Skin Health |
| Operating Cash Flow | $3.7B | $4.1B | $4.2B | Growing consistently |
The FY2025 net income decline from $2.9B to $2.1B is explained by the filing: "In the fourth quarter of 2025, we took a non-cash, aftertax impairment charge of $794 to adjust the carrying values of goodwill and intangible assets related to the skin health business." Excluding this charge, underlying earnings grew.
The filing reports shipping and handling costs separately from COGS. If included, gross margin would be "lower by 880 bps in 2025" — meaning the comparable gross margin is approximately 51.3%, still excellent for a consumer staples company.
Cash Flow: A Cash Machine
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating Cash Flow | $3.7B | $4.1B | $4.2B |
| Net Income | $2.3B | $2.9B | $2.1B |
| **CFFO / Net Income** | **1.63** | **1.42** | **1.97** |
| CapEx | $705M | $561M | $564M |
| Free Cash Flow | $3.0B | $3.5B | $3.6B |
CFFO/NI of 1.97 means nearly $2 in cash for every $1 of reported income. The elevated FY2025 ratio partially reflects the non-cash impairment charges inflating the gap. Free cash flow of $3.6B is roughly 18% of revenue — extremely capital-efficient.
The equity explanation: Colgate's balance sheet shows shareholders' equity of just $54M (per the screening data, goodwill+intangibles/equity = 8,626%). This is because Colgate has repurchased more shares over its history than it has earned in cumulative retained earnings. The company deliberately operates with negative or near-zero equity, funded entirely by operating cash flow and debt. With Debt/EBITDA of 2.2x and interest coverage of 15.9x, this is a managed strategy, not a sign of distress.
The 18-Point Screening
Revenue Quality
| # | Check | Result | Detail |
|---|---|---|---|
| A1 | DSO Change | ✅ | DSO 30 days, +2 days YoY |
| A2 | AR vs Revenue Growth | ⚠️ | AR growth 10.1% vs revenue 1.4% |
| A3 | Revenue vs CFFO | ✅ | Revenue +1.4%, CFFO +2.2% |
A2 — AR growing faster than revenue. DSO increased from 28 to 30 days. In a global consumer products company operating in 200+ countries, this likely reflects timing and mix rather than credit deterioration. But it warrants monitoring — if FY2026 shows the same divergence, it could indicate loosening trade terms in emerging markets.
Expense Quality
| # | Check | Result | Detail |
|---|---|---|---|
| B1 | Inventory vs COGS | ✅ | Inventory +2.3% vs COGS +2.4% |
| B2 | CapEx vs Revenue | ✅ | CapEx +0.5% vs revenue +1.4% |
| B3 | SG&A Ratio | ✅ | SG&A/Gross Profit = 64.5% |
| B4 | Gross Margin | ✅ | 60.1%, -0.4pp (stable) |
All clean. Expenses track revenue closely with no signs of cost inflation or capitalization games.
Cash Flow Quality
| # | Check | Result | Detail |
|---|---|---|---|
| C1 | CFFO vs Net Income | ✅ | CFFO/NI = 1.97 |
| C2 | Free Cash Flow | ✅ | FCF $3.6B, FCF/NI = 1.70 |
| C3 | Accruals Ratio | ✅ | -12.7% (excellent) |
| C4 | Cash vs Debt | ❌ | Cash $1.3B covers only 15% of debt $8.6B |
C4 is structural. Colgate operates a "capital-light, return-everything" model. $4.2B in annual CFFO against $8.6B in debt means the entire debt could theoretically be retired in roughly two years of operating cash flow. Interest coverage of 15.9x confirms zero debt service stress.
Balance Sheet
| # | Check | Result | Detail |
|---|---|---|---|
| D1 | Goodwill + Intangibles | ❌ | $4.7B = 8,626% of equity |
| D2 | Leverage | ✅ | Debt/EBITDA = 2.2x |
| D3 | Soft Asset Growth | ✅ | Other assets +1.3% vs revenue +1.4% |
| D4 | Asset Impairment | — | No write-off data |
D1 — The equity denominator is the issue, not the numerator. Goodwill of $3.1B is modest for a $20B revenue company. The 8,626% ratio is purely a function of equity being $54M due to cumulative buybacks exceeding retained earnings.
Acquisition Risk
| # | Check | Result | Detail |
|---|---|---|---|
| E1 | Serial Acquirer FCF | ✅ | FCF after acquisitions positive |
| E2 | Goodwill Surge | ✅ | Goodwill+Intangibles -7% YoY |
Manipulation Score
| # | Check | Result | Detail |
|---|---|---|---|
| F1 | Beneish M-Score | ✅ | -3.02 (clean) |
Key Risks from the 10-K
1. Skin Health — $794M After-Tax Impairment Charge
PwC's critical audit matter: "In the fourth quarter of 2025, management concluded that changes in circumstances in the skin health reporting unit triggered the need for an interim impairment review of its goodwill. Management completed a quantitative impairment test for goodwill and recorded a goodwill impairment charge of $582 million." The total after-tax charge including intangible write-downs was $794M. Skin Health goodwill post-impairment: $51M.
2. North America Revenue Declining
Per segment data: "Net sales in North America decreased 1.6% in 2025 to $4,045, driven by volume declines of 1.4%, net selling price decreases of 0.2% and negative foreign exchange of 0.1%." The filing attributes this to "decreases in Personal Care" — the company's home market is shrinking.
3. Foreign Currency Exposure
Operating in 200+ countries means significant FX risk. The filing notes pension discount rates, expected return assumptions, and global tax positions all carry estimation uncertainty. With approximately two-thirds of employees based outside the US, currency volatility directly impacts reported earnings.
4. Pension and Actuarial Assumptions
The filing discloses U.S. pension plan assumptions: discount rate 5.51%, expected return 6.50%. A "1% change in the assumed rate of return on plan assets of the U.S. pension plans would impact future Net income by approximately $12" million. With actual returns ranging from -1% to 10% over various periods, the assumed return embeds estimation risk.
Summary
Grade: F on paper, but the underlying business is a fortress.
Colgate-Palmolive's two red flags — cash-to-debt and goodwill-to-equity — are artifacts of a deliberate capital return strategy that has reduced shareholder equity to near zero through decades of buybacks. The actual business generates 60% gross margins, $4.2B in CFFO, interest coverage of 15.9x, and an M-Score of -3.02. The genuine risk is the Skin Health impairment ($794M after-tax in FY2025) and declining North American organic sales. The Z-Score of 6.22 confirms this is far from financial distress. This is the rare F-grade company where the screening system's mechanical rules conflict with fundamental reality.
**Disclaimer**: This report is based on Colgate-Palmolive's FY2025 10-K filed with SEC EDGAR on February 23, 2026. This is NOT investment advice.
Data: SEC EDGAR 10-K + Yahoo Finance
Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 1 critical audit matter — Skin Health goodwill impairment)
Fiscal year ended: December 31, 2025